RADIOIODINE SERVICE - THYROID CANCER

This tender concerns the provision of a radioiodine service specifically for the treatment of thyroid cancer. Radioiodine therapy, also known as radioactive iodine treatment, is a medical procedure commonly used to treat certain types of thyroid cancer, particularly differentiated thyroid cancers like papillary and follicular types. The service likely involves the administration of radioactive iodine isotopes, typically Iodine-131 (I-131), to patients diagnosed with thyroid cancer. This radioactive substance is absorbed by thyroid cells, including any remaining cancerous cells after surgery, leading to their destruction. The tender may cover various aspects of this service, including the procurement and handling of radioactive materials, patient preparation, administration of the therapy, post-treatment monitoring, and management of radioactive waste. It is essential for healthcare providers to have specialized facilities and trained personnel to safely and effectively deliver this treatment. The scope of the service could also extend to diagnostic procedures utilizing radioiodine, such as radioactive iodine uptake scans, which help assess thyroid function and detect residual or metastatic thyroid cancer. The objective is to ensure patients receive comprehensive and high-quality care for thyroid cancer through specialized radioiodine treatments.

This is a services contract in the health and medical services, environment and climate and information and communication technology sectors, with a focus on Laboratory. Located in Chile, Latin America, this opportunity is open to firms and consortiums.

Published through Chile Mercado Publico, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the health and medical services sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.